NCT02698215View on ClinicalTrials.gov

Combining Varenicline and Naltrexone for Smoking Cessation

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Nicotine DependenceAlcohol Use Disorder
Interventions
DRUG

Varenicline

Varenicline 1 mg twice daily

DRUG

Varenicline plus Naltrexone

Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily

Trial Locations (1)

90095

UCLA Addictions Laboratory, Los Angeles

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of California, Los Angeles

OTHER

NCT02698215 - Combining Varenicline and Naltrexone for Smoking Cessation | Biotech Hunter | Biotech Hunter